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Integrative transcriptomic analysis reveals key
drivers of acute peanut allergic reactions
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Mechanisms driving acute food allergic reactions have not been fully characterized. We
profile the dynamic transcriptome of acute peanut allergic reactions using serial peripheral
blood samples obtained from 19 children before, during, and after randomized, double-blind,
placebo-controlled oral challenges to peanut. We identify genes with changes in expression
triggered by peanut, but not placebo, during acute peanut allergic reactions. Network analysis
reveals that these genes comprise coexpression networks for acute-phase response and pro-
inflammatory processes. Key driver analysis identifies six genes (LTB4R, PADI4, IL1R2,
PPP1R3D, KLHL2, and ECHDC3) predicted to causally modulate the state of coregulated net-
works in response to peanut. Leukocyte deconvolution analysis identifies changes in neu-
trophil, naive CD4+ T cell, and macrophage populations during peanut challenge. Analyses in
21 additional peanut allergic subjects replicate major findings. These results highlight key
genes, biological processes, and cell types that can be targeted for mechanistic study and
therapeutic targeting of peanut allergy.
DOI: 10.1038/s41467-017-02188-7 OPEN
1 Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. 2Department of Biochemistry and
Molecular Genetics, University of Louisville School of Medicine, Louisville, KY 40202, USA. 3 Icahn Institute for Genomics and Multiscale Biology, Icahn
School of Medicine at Mount Sinai, New York, NY 10029, USA. 4Department of Anesthesia, Hospital for Special Surgery, New York, NY 10021, USA.
5Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. 6 eEmmes Corporation, Rockville, MD 20850, USA.
7Department of Pediatrics, Johns Hopkins University, Baltimore, MD 21287, USA. 8Department of Pediatrics, University of North Carolina, Chapel Hill, NC
27599, USA. 9 Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children’s Hospital, Little Rock, AS 72202, USA.
10 Department of Pediatrics, National Jewish Health, Denver, CO 80206, USA. C.T. Watson and A.T. Cohain contributed equally to this work. E.E. Schadt and
S. Bunyavanich jointly supervised this work. Correspondence and requests for materials should be addressed to S.B. (email: supinda@post.harvard.edu)
NATURE COMMUNICATIONS |8:  1943 |DOI: 10.1038/s41467-017-02188-7 |www.nature.com/naturecommunications 1
12
34
56
78
9
0
Peanut allergy is a clinical and public health problem thataffects 2–5% of US school-age children, with evidence ofincreasing prevalence1. Peanut allergy is defined as an
adverse health effect arising from a specific immune response that
occurs reproducibly upon exposure to peanut, leading to acute
symptoms such as hives, swelling, respiratory difficulty, cardio-
vascular compromise, gastrointestinal disturbance, and/or ana-
phylaxis that can be life-threatening2. The development of peanut
allergy involves deviation from mucosal and cutaneous immune
tolerance, such that dietary antigens presented by antigen pre-
senting cells lead to an adverse Th2-cell skewed response, priming
of innate immune effector cells, and alteration of cytokine milieu
such that subsequent food allergen-specific antigen exposure
leads to IgE-mediated acute reactions3. In addition to immediate
symptoms of the allergic response, peanut allergy has broader
long-term effects, impacting nutrition, emotional health, and
lifestyle2. There is presently no cure for peanut allergy, and our
understanding of its causation and pathobiology remain limited.
Gene expression studies in food allergic individuals have pro-
vided some insight into the potential molecular processes
underlying peanut allergy. Differentially expressed genes identi-
fied in food allergic individuals indicate that underlying pertur-
bations in immune system processes contribute to the
development of food allergy4, 5. For example, transcriptome-wide
gene expression profiles in stimulated CD4+ T cells collected from
allergic individuals at infancy prior to disease onset, and matched
non-allergic controls, revealed significant expression differences
for >2000 genes, which together represented a signature of
reduced capacity for T cell proliferation in allergic individuals4.
Comparisons of gene expression levels in circulating peripheral
blood mononuclear cells between 17 fruit and/or latex allergic
adults and four controls revealed global differences in the resting
state, including the differential expression of genes involved in
helper T cell cytokine signaling5. Dysregulation of genes involved
in various immune processes has also been reported in other
allergic diseases6, 7.
Although studies conducted to date have illuminated factors
and genes associated with food allergy susceptibility, little
emphasis has been placed on characterizing genes that mediate
acute food allergic reactions. Furthermore, studies attempting to
address such questions have not done so in human cohorts using
in vivo oral food challenges. Thus, limited actionable information
exists that can be used to inform targeted development of novel
therapeutics for prevention of acute reactions. In this study, we
take an in vivo approach (Fig. 1) to comprehensively profile
changes in the transcriptome that occur during the course of
acute peanut allergic reactions. We apply RNA-sequencing
(RNA-seq) to serial peripheral blood samples from a cohort of
peanut allergic children before, during, and after randomized,
double-blind, placebo-controlled oral peanut challenges. Using
these data, we integrate results from linear mixed-effects (lme)
models, leukocyte deconvolution, weighted gene coexpression
network analysis (WGCNA), and probabilistic causal gene net-
work modeling to identify causal key driver genes, biological
processes, and cell types involved in acute peanut allergic reac-
tions. Support for our major findings is then gained from repli-
cation in an additional 21 peanut allergic subjects.
Results
Clinical characteristics of the peanut allergic cohort. Twenty-
one children with suspected peanut allergy completed rando-
mized, double-blind, placebo-controlled oral food challenges to
peanut, performed according to a modified AAAAI/EAACI
PRACTALL protocol8, 9. Under close medical supervision with
blinding of subjects and staff, subjects ingested incremental
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Fig. 1 Overview of study design and analytical flow. Schematic outlining the
clinical phenotyping, sample collections, RNA-sequencing, and analyses
conducted. A discovery cohort consisting of 19 peanut allergic subjects,
underwent physician-supervised, double-blind oral food challenges to both
peanut and placebo, with the order of challenges randomized. For each
subject, whole blood samples at baseline, 2 h, and 4 h were each collected
during the peanut and placebo challenges. RNA-sequencing was performed
on all samples and used for the following analyses outlined in gray: (1)
linear mixed-effects model analyses to identify peanut genes (i.e., genes
with expression changes in response to peanut, but not placebo, during
acute peanut allergic reactions); (2) weighted gene coexpression network
analysis (WGCNA) to identify modules of co-expressed genes as broader
constructs of biologic function; and (3) leukocyte deconvolution analysis to
identify cellular response during the acute peanut allergic reactions. Peanut
genes identified by linear mixed-effects model analysis and WGCNA were
projected onto a probabilistic causal gene network. Functional biologic
processes implicated by WGCNA and peanut genes were investigated
further using gene ontology enrichment analysis. Key driver analysis was
implemented to identify key causal modulators of the peanut response
module enriched for peanut genes. A replication cohort of 21 peanut allergic
subjects analogously profiled was used to replicate major findings from this
study (steps for which replication analyses were conducted are indicated
with maroon arrows)
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amounts of peanut at 20 min intervals until an allergic reaction
occurred or until the cumulative dose of 1.044 grams protein was
ingested. In a similar fashion and on a different day, the same
subjects ingested incremental doses of placebo oat powder. The
order of peanut and placebo challenges was randomized, and all
subjects completed both peanut and placebo challenges. Periph-
eral blood samples were drawn before, during, and at the end of
each challenge.
Nineteen of the 21 children reacted to peanut, and none of the
subjects reported symptoms during the placebo challenge; clinical
characteristics are shown in Table 1. The two children who met
inclusion criteria and completed the challenges, but had no
reaction to peanut, were considered not peanut allergic and were
excluded from further study. Among the 19 peanut allergic
children, peanut sIgE ranged from 1.21 to >100 kUA/L, and
peanut skin prick test wheal ranged from 4.5 to 39.5 mm.
All children reacted within the first 2 h of the peanut challenge.
Five children with peanut allergy reacted to the first dose of
peanut, with symptoms of an allergic reaction following just 1 mg
of peanut protein. The median cumulative dose at first objective
symptom among the peanut allergic children was the third dose
(10 mg dose for a cumulative intake of 14 mg peanut protein).
The most common symptom elicited by peanut was distress,
followed by throat tightness, urticaria, angioedema, vomiting, and
rhinorrhea. All children received antihistamines and 58% were
administered epinephrine.
Identifying genes associated with peanut allergic reactions. The
primary aims of this study were to characterize gene expression
signatures, functional processes, and causal key drivers of acute
peanut allergic reactions. To do this, during each peanut and
placebo challenge, we collected peripheral blood from each sub-
ject at zero hours (baseline, pre-challenge), 2 h (during challenge)
and 4 h (end of challenge) from challenge start, totaling 6 samples
per subject for RNA-seq (Fig. 1). This design enabled us to exe-
cute analyses such that each subject served as their own control
over time and exposure (peanut vs. placebo). Six samples were
collected from each of the 19 subjects, except for two participants
for whom samples were obtained during peanut challenge only,
resulting in a total of 108 samples collected.
Following data processing, normalization, and quality control,
one outlier sample was removed (Supplementary Figure 1),
resulting in RNA-seq data (n = 17,337 genes) for 107 blood
samples (placebo n = 51; peanut n = 56) across the 19 peanut
allergic subjects. To identify genes associated with acute peanut
allergic reactions, we used lme modeling10, which allowed us to
collectively and statistically assess, across all individuals in this
peanut allergic cohort, within-individual changes in gene
expression across all time points in response to peanut and not
placebo (see Methods). The top 30 genes identified by this
analysis (Bonferroni-corrected P< 0.01) are shown in Table 2;
functional information for each gene is summarized in Supple-
mentary Table 1. Because effect size estimates from lme models
can be less intuitive, changes in gene expression between the
means at baseline and four-hour time points for the peanut
challenge are displayed in Table 2 as a more intuitive measure of
effect size. As Bonferroni correction is often considered overly
conservative, an extended set of genes significant at P< 0.005 was
used for many of the downstream analyses that follow
(Supplementary Data 1). For ease, we refer to this extended set
of peanut allergen response genes henceforth as “peanut genes.”
Gene expression levels for six selected peanut genes are plotted
in Fig. 2 as examples of patterns observed for genes identified by
lme modeling; these genes are also the six key drivers identified by
causal network analyses conducted below. For context, plots for
the top 30 peanut genes are provided in Supplementary Fig. 2.
Consistent with the activation of pro-inflammatory processes, the
majority of peanut genes were upregulated with peanut exposure,
with 65% (1411/2168) exhibiting increased gene expression at
four hours after initial exposure to peanut. Across all peanut
genes, we observed a greater magnitude of gene expression
change between baseline and four hours (mean differences of 0.24
log2-counts per million (c.p.m.)) compared to baseline and two
hours (mean difference 0.04 log2-c.p.m.).
Leukocyte compositional changes in peanut allergic reactions.
Given that the allergic response involves the activation, differ-
entiation, and recruitment of various immune cell types, we tested
for changes in the distribution of leukocyte cell fractions during
acute peanut allergic reactions. Employing a leukocyte cell-type
deconvolution algorithm11, we inferred the proportions of 19
leukocyte populations from RNA-seq expression profiles of each
sample and time point (Fig. 3a). Neutrophils, naive CD4+ T cells,
and monocytes were the predominant cell types observed, col-
lectively representing 70% of cells on average across samples. In
contrast, the remaining cell types each had individual mean
fractions <10%.
Analogous to our gene expression analysis, we used lme models
to identify leukocyte cell fractions with significant changes over
time in response to peanut but not placebo. We observed
significant differences in three specific cell types after correction
for multiple testing (Fig. 3b): M0 macrophages (FDR = 0.016),
neutrophils (FDR = 0.016), and naive CD4+ T cells (FDR = 0.018).
Whereas the fraction of both macrophages and neutrophils
continuously increased over time during the peanut challenge,
Table 1 Characteristics of the peanut allergic discovery
cohort (n= 19) and replication cohort (n= 21)
Discovery Cohort
(n= 19)
Replication Cohort
(n= 21)
Sex: Female 7 (36.8%) 7 (33.3%)
Age: years 12.0 (4.0) 11.0 (5.0)
Parental allergy 16 (84.2%) 21 (100.0%)
Peanut sIgE: kUa/L 68.0 (82.8) 87.4 (140.5)
Peanut skin prick test: mm 12.0 (6.0) 13.0 (11.0)
Cumulative dose at first
objective symptom: g peanut
protein
0.014 (0.44) 0.044 (0.14)
Cumulative successfully
consumed dose: g peanut
protein
0.144 (0.48) 0.144 (0.40)
Symptoms experienced during peanut challenge
Distress 13 (68.4%) 14 (66.7%)
Throat tightness 9 (47.4%) 6 (28.6%)
Rhinorrhea 3 (15.8%) 2 (9.5%)
Rash 1 (5.3%) 4 (19.0%)
Rubbing of eyes, nose, or
scratching
2 (10.5%) 3 (14.3%)
Urticaria: 1–2 lesions 3 (15.8%) 6 (28.6%)
Urticaria: >3 lesions 2 (10.5%) 5 (23.8%)
Angioedema 4 (21.1%) 9 (42.9%)
Vomit: single 2 (10.5%) 2 (9.5%)
Vomit: multiple times 1 (5.3%) 0 (0.0%)
Abdominal pain: severe 2 (10.5%) 5 (23.8%)
Diarrhea 0 (0.0%) 1 (4.8%)
Wheeze 0 (0%) 1 (4.8%)
Stridor 1 (5.3%) 0 (0.0%)
Hypotension 0 (0%) 0 (0.0%)
Number (percent) or Median (IQR) are shown
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but not placebo, there was a reduction in naive CD4+ T cells at
four hours compared to baseline (Fig. 3b). Raw and corrected P-
values from this analysis are provided in Supplementary Table 2.
To treat severe reactions, some subjects in our study (n = 11)
were given epinephrine during peanut challenge. Because
epinephrine can impact cell numbers in peripheral blood12, 13,
we stratified our data to assess whether the same trends were
observed in subjects who did and did not receive epinephrine
(Supplementary Fig. 3). Consistent with the combined results, we
observed increased fractions of macrophages and neutrophils, and
a decreased fraction of naive CD4+ T cells, after peanut challenge
in both the epinephrine treated and untreated strata. However,
particularly for neutrophils and CD4+ T cells, the effects were
more pronounced in subjects who received epinephrine, which
could be attributable to the fact that these individuals had more
severe allergic reactions. To directly test whether this difference
was due to reaction severity vs. epinephrine treatment, an
experimental design barring epinephrine treatment in subjects
with severe reactions would be needed; however, this is not
ethically possible in human subjects given the risk of anaphylaxis
and death with untreated severe allergic reactions.
Replication of gene expression and leukocyte signatures. To
assess the robustness of the changes in gene expression and leu-
kocyte fractions observed, we sought to replicate our findings in an
independent replication cohort of 21 peanut allergic children, with
clinical characteristics similar to those of the discovery cohort
(Table 1). Each of the 21 individuals underwent analogous double-
blind, placebo-controlled peanut challenges using the same sample
collection protocol as the discovery cohort. We used RNA-seq
data generated from whole blood collected at baseline, two hours,
and four hours of the peanut challenge to test for gene expression
changes that occurred in response to peanut. Of the top 30 genes
identified in the discovery cohort, 28 exhibited statistically sig-
nificant (P< 0.05) changes in expression during peanut challenge
in the replication cohort (Table 2), representing a significant
enrichment (OR = 27.9, Fisher’s exact test P = 9.5 × 10−12) over
that expected by chance. Boxplots depicting expression data in this
replication cohort for each of the top 30 genes presented in
Table 2 are shown in Supplementary Fig. 4, showing concordant
directions of gene expression change for all genes during peanut
challenge relative to the discovery cohort.
We next used transcriptome profiles from the replication
cohort to perform peripheral blood leukocyte deconvolution
(Supplementary Fig. 5a) and lme modeling to identify changes in
the proportions of cell subsets during peanut challenge. The same
three cell types identified in the discovery cohort were again
significant in the replication cohort (Supplementary Fig. 5b; M0
macrophages (FDR = 0.0053); neutrophils (FDR = 0.0013); naive
CD4+ T cells (FDR = 0.0038)).
Peanut genes enriched in an acute-phase response module. To
investigate the biological context and relationships of peanut
genes identified by our analyses, we constructed transcriptome-
wide gene networks in the discovery cohort using WGCNA14.
WGCNA identifies modules of co-expressed genes (i.e., groups of
Table 2 Top 30 peanut allergen response genes (peanut genes) identified by linear mixed-effects models (Bonferroni-corrected
P< 0.01) in the discovery cohort and their corresponding results in the replication cohort
Discovery Cohort (n= 19) Replication Cohort (n= 21)Gene
P-value Bonferroni P-value Peanut T4 vs. T0 Δ log2-cpma P-value Peanut T4 vs. T0 Δ log2-cpma
PLP2 1.24 × 10−08 2.00 × 10−04 0.55 3.81 × 10−03 0.38
LY9 1.43 × 10−08 2.00 × 10−04 −0.48 4.34 × 10−02 −0.22
APLP2 1.57 × 10−08 2.00 × 10−04 0.62 1.68 × 10−04 0.40
AGPAT9 3.21 × 10−08 5.004 × 10−04 1.18 9.95 × 10−06 0.78
NOV 3.56 × 10−08 6.00 × 10−04 0.97 9.86 × 10−03 0.45
DGKG 5.94 × 10−08 0.001 0.73 8.85 × 10−04 0.48
BST1 9.64 × 10−08 0.0016 1.11 6.86 × 10−04 0.68
CRK 1.05 × 10−07 0.0018 0.54 4.01 × 10−04 0.31
CD22 1.09 × 10−07 0.0018 −0.55 3.89 × 10−01 −0.16
MOSC1 1.75 × 10−07 0.003 1.37 7.29 × 10−05 0.92
PLXDC1 1.76 × 10−07 0.003 −0.31 2.85 × 10−01 −0.15
PADI4 1.93 × 10−07 0.0033 1.51 4.21 × 10−04 0.86
FCAR 1.95 × 10−07 0.0033 1.49 5.68 × 10−04 1.05
DDX55 2.22 × 10−07 0.0038 −0.22 2.83 × 10−02 −0.17
PLCG2 2.66 × 10−07 0.0046 0.55 1.99 × 10−03 0.28
SULF2 2.75 × 10−07 0.0047 0.73 1.95 × 10−06 0.61
LTB4R 2.83 × 10−07 0.0049 1.21 2.03 × 10−03 0.51
RBP7 2.86 × 10−07 0.0049 0.97 1.81 × 10−03 0.68
OSCAR 2.92 × 10−07 0.005 0.77 1.69 × 10−03 0.50
MMP9 3.29 × 10−07 0.0057 2.24 2.79 × 10−04 1.36
JDP2 3.42 × 10−07 0.0059 1.26 5.88 × 10−04 0.75
ACSS2 3.49 × 10−07 0.006 0.52 7.17 × 10−04 0.26
CCDC164 3.50 × 10−07 0.006 1.67 3.07 × 10−04 1.22
EPHB4 3.70 × 10−07 0.0064 1.31 1.86 × 10−05 0.81
C5orf39 3.89 × 10−07 0.0067 −0.21 1.11 × 10−02 −0.18
SLC26A8 4.14 × 10−07 0.0071 1.27 2.3 × 10−05 0.92
DIRC2 4.18 × 10−07 0.0072 0.76 3.73 × 10−04 0.53
BMX 4.58 × 10−07 0.0079 2.05 6.58 × 10−05 1.28
LILRA3 4.66 × 10−07 0.008 1.26 1.69 × 10−03 0.63
FCRL3 5.27 × 10−07 0.009 −0.43 3.67 × 10−03 −0.45
aBecause effect size estimates from lme models are less intuitive, changes in gene expression between the means at baseline and four-hour time points for the peanut challenge are displayed as a more
intuitive estimate of effect size; Bolded gene names are those for which significant P-values were observed in both the Discovery and Replication cohorts
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genes with similar expression profiles and interconnectivity
across experimental samples), that can serve as broader con-
structs of gene expression beyond the single gene level15. Using
WGCNA, we identified 13 coexpression modules (Supplementary
Table 3). To identify modules associated with acute peanut
allergic reaction, we tested for enrichment of peanut genes in each
module. Only the blue coexpression module was significantly
enriched for peanut genes. 1223 (51%) of the 2381 genes in that
module were peanut genes, equivalent to a 4.1-fold enrichment
over that expected by chance (Fisher’s exact test P = 1.2 × 10−304)
(Fig. 4a; Supplementary Table 3). We will henceforth refer to the
blue module as the “peanut response module,” given it was the
only module enriched for peanut genes.
To gain insight into the collective putative function of genes
within the peanut response module, we next performed gene
ontology (GO) analysis16. This revealed significant enrichments
of the peanut response module for inflammatory processes,
including acute-phase response (fold enrichment = 3.5; FDR =
6.5 × 10−3), acute inflammatory response (fold enrichment = 2.8,
FDR = 2.9 × 10−3), positive regulation of I-kappa-B kinase/NF-
kappa-B signaling (fold enrichment = 1.9; FDR = 1.8 × 10−3), and
lymphocyte activation (fold enrichment = 1.7; FDR = 3.0 × 10−3).
The GO biological process terms associated with the peanut
response module at FDR < 0.01, sorted by fold enrichment, are
shown in Fig. 4b. A complete list of these GO terms and
associated genes are provided in Supplementary Data 2. Although
no other coexpression module identified by WGCNA was
enriched for peanut genes after correction, we show the top
biological processes associated with these other modules for
comparison (Fig. 4a). To further enhance our understanding of
the peanut response module, we examined GO biologic process
terms for the upregulated and downregulated peanut genes in this
module separately (Fig. 4c, d). Whereas the upregulated genes are
involved in inflammation, the downregulated genes regulate
macromolecule metabolism; P-values and enrichment statistics
from this analysis are provided in Supplementary Data 3.
Identifying causal key drivers of the peanut response module.
Although integration of our peanut gene analysis with WGCNA
provided strong evidence for a link between acute peanut allergic
reactions and the peanut response module, this type of analysis is
associative and thus cannot on its own reveal causal relationships
among genes in the implicated module. Elucidating the con-
nectivity structure within these modules can lead to the identi-
fication of key driver genes that are predicted to modulate the
regulatory state of the module, and be of high interest to prioritize
as causal to acute peanut allergic reactions. We have previously
integrated genetic, transcriptome and other high-throughput data
into probabilistic causal gene networks as one approach to
uncover key driver genes in disease associated networks/mod-
ules17, 18. This type of data-driven, directed approach provides
systems-wide context for understanding known and novel reg-
ulators and processes for a disease. We sought to apply such
approaches here to identify key driver genes of the peanut
response module.
Given the lack of large-scale gene expression data sets
generated from individuals with peanut or other food allergies,
which would be needed to construct accurate probabilistic causal
gene networks19, we explored the availability of alternative data
sets that could be used to model gene networks associated with
inflammation (consistent with processes identified by WGCNA
analyses above). We constructed a directed probabilistic causal
gene network using peripheral blood gene expression data and
expression quantitative trait loci (eQTL) from 526 patients with
inflammatory bowel disease (IBD)20. Although IBD is distinct
from food allergy, both conditions are due to maladaptive
immune reactions to antigens presented to the gastrointestinal
tract in genetically susceptible individuals, and there is an
9
LTB4R P=1.8 × 10–7
P=1.9 × 10–7
ECHDC3 IL1R2
P=3.2 × 10–5 P=7.3 × 10–5PPP13RD KLHL2
P=1.5 × 10–5P=6.59 × 10–5
8
8
8
6
6
10
4
4
7
6
5
4
3
2
0
N
or
m
al
iz
ed
 lo
g2
 (
cp
m
)
N
or
m
al
iz
ed
 lo
g2
 (
cp
m
)
N
or
m
al
iz
ed
 lo
g2
 (
cp
m
)
N
or
m
al
iz
ed
 lo
g2
 (
cp
m
)
7
6
5
9
6.5
6.0
5.5
5.0
4.5
8
N
or
m
al
iz
ed
 lo
g2
 (
cp
m
)
N
or
m
al
iz
ed
 lo
g2
 (
cp
m
)
7
6
5
Peanut Placebo
Ba
se
lin
e
Ba
se
lin
e
2 
h
2 
h
4 
h
4 
h
Peanut Placebo
Ba
se
lin
e
Ba
se
lin
e
2 
h
2 
h
4 
h
4 
h
Peanut Placebo
Ba
se
lin
e
Ba
se
lin
e
2 
h
2 
h
4 
h
4 
h
PADI4
Fig. 2 Peanut genes exhibit significant changes in gene expression following challenge to peanut but not placebo. Boxplots displaying log2-cpm expression
values for six selected peanut genes in the 19 peanut allergic discovery cohort subjects at three time points (baseline, during challenge (2 h), and end of
challenge (4 h)) for both peanut and placebo challenges. The majority of the peanut genes we identified, including the six selected genes shown, exhibited
increased expression with peanut challenge. To identify genes with expression changes that occurred specifically during peanut but not placebo challenge,
we used linear mixed-effects models to test for a significant contribution of the interaction between time and peanut exposure on gene expression. P-
values for the likelihood ratio test between the test model and null lme models are shown for each gene
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association between IBD and atopic diseases, including food
allergy21, 22. We reasoned that there is some overlap between the
two conditions with regard to chronic immune dysregulation and
pro-inflammatory processes such that the topology and major
edges of the underlying disease network architecture in IBD could
inform gene coregulation relevant to the inflammatory response
to peanut.
To narrow in on the component of the constructed
probabilistic causal gene network most relevant to acute peanut
allergic reactions, we projected peanut genes belonging to the
WGCNA peanut response module onto this network. The
projection consisted of overlapping genes from the intersection
of these genes and all genes in the network, identifying all genes
in the network that are within a path length of one node in this
overlap, and then identifying the largest connected graph
(subnetwork) from this set of nodes and all associated edges.
The subnetwork identified from this projection was composed of
1029 genes, including 500 genes belonging to both the peanut
response module and peanut gene set, representing a 4.7-fold
enrichment over that expected by chance (Fisher’s exact test P =
3.81 × 10−272). This indicated that the peanut response module
constructed from our study was highly conserved in the
probabilistic causal network constructed from the IBD cohort.
To predict genes that modulate the regulatory state of the
peanut response module, we employed key driver analysis (KDA),
an algorithm that mathematically identifies causal modulators of
the regulatory state of functionally relevant gene groups17. Key
drivers have been found to be reproducible and successfully
validated in different contexts23. KDA identified 26 key drivers
(FDR< 0.05) of the peanut response module in the IBD network,
and these key drivers were significantly enriched for genes in the
identified subnetwork (OR = 82.6, Fisher’s exact test P= 9.65 × 10
−20) (Supplementary Table 4). The relationship between key
drivers with the peanut genes, and genes belonging to the peanut
response module are depicted in Fig. 5. This hierarchical structure
of the network, reflects an ordering of the key driver genes in
which key drivers at the highest level have the most upstream
effects on modulating the state of genes at the lowest level, which
specifically comprise peanut genes and genes belonging to the
peanut response module. As the distance from the bottom
increases, so too does the enrichment at each level for being a key
driver. The higher up in the response cascade, the higher the odds
ratio (OR 274.1, Fisher’s exact test P = 6.0 × 10−16 for the top
level). Resolving the structure of these networks allows for the
identification of those driver genes that are causally associated
with the expression of peanut genes at the most upstream points
in the response cascade.
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To ensure that the IBD network was capturing biology relevant
to peanut allergy, we constructed a validation causal gene network
using the peanut allergic discovery and replication cohorts
(Table 1). As context, we used the IBD network as our discovery
causal network because it could be built on a much larger data set
(n = 526) with genetic prior information (expression quantitative
trait loci (eQTL)), thus enabling construction of a robust and
informative causal network19, 24, 25. The peanut causal network
we built is not as robust as the IBD network given the limited
sample size for its construction and lack of eQTLs available as
input, and was therefore used to validate findings from the IBD
network. Indeed, when we performed the same subnetwork
analysis as above but in the peanut network, the overlap between
the IBD and peanut subnetworks was 3-fold enriched over that
expected by chance (Fisher’s exact test P = 3.3 × 10−224). Further,
KDA of the peanut allergy-specific causal network identified key
drivers significantly overlapping those from the IBD network (OR
16.8, Fisher’s exact test P= 2.4 × 10−7), lending confidence to our
causal network findings.
Six key driver genes (LTB4R, PADI4, IL1R2, PPP1R3D, KLHL2,
and ECHDC3) in particular were highlighted by the combined
interpretation of the lme models, WGCNA, and KDA, as these
were the only genes that met all three criteria of being: (1) peanut
genes with a significant change in expression with peanut but not
placebo exposure; (2) members of the WGCNA peanut response
module; and (3) top level key driver genes in the hierarchical
visualization of the network, predicted to causally modulate the
state of peanut genes and peanut response module members at
the most proximal level (Fig. 5). To illustrate the relationship
between these six key drivers of highest interest, Fig. 6 shows their
relationship within the probabilistic causal gene network, as well
as their cellular context based on prior knowledge. Two of these
top layer key drivers, LTB4R and PADI4, were peanut genes by
the strictest significance criteria (Bonferroni-corrected P< 0.01)
(Table 2; Fig. 2). In addition, LTB4R and PADI4 have previously
demonstrated roles in inflammatory and immune-related
diseases26, 27, as does IL1R2, another top layer key driver28, 29.
Discussion
In this study, we collected and analyzed serial peripheral blood
transcriptomic profiles from a cohort of peanut allergic children
undergoing double-blind, placebo-controlled oral food challenges
to identify six causal key driver genes (LTB4R, PADI4, IL1R2,
PPP1R3D, KLHL2, and ECHDC3) of high interest in acute peanut
allergic reactions. Analysis of a second peanut allergic cohort of
21 children replicated our major findings. The results of this
study provide a data-driven, circumscribed set of high-yield gene
targets for directed mechanistic studies of peanut allergy, the
most common cause of food-related anaphylaxis and death in the
United States.
Currently, allergen avoidance and prompt care of allergic
reactions remain the standard treatment strategy for food allergic
individuals. Although immunotherapy for desensitization and/or
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Fig. 4 Identification and characteristics of the peanut response coexpression module. a Fold enrichment of peanut genes (P< 0.005) in the 13 coexpression
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black module. b The top thirty GO terms associated with the peanut response module, ranked by fold enrichment. Horizontal dotted lines in both a and b
correspond to a fold enrichment= 1. c GO terms associated with upregulated genes (FDR≤ 0.05) in the peanut response module, with size of box inversely
corresponding to FDR. d GO terms associated with downregulated genes (FDR≤ 0.05) in the peanut response module, with size of box inversely
corresponding to FDR
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sustained unresponsiveness have demonstrated progress, immu-
notherapy is not effective for all individuals30–32, carries sig-
nificant adverse side effects, may not have long-term efficacy, and
is not ready for generalized clinical implementation33. In addi-
tion, the fact that unexpected acute reactions are responsible for
the majority of mortalities associated with food allergy, stresses
the need for better understanding the molecular processes med-
iating such reactions.
A major strength of this study is that the design (Fig. 1)
allowed for rigorous characterization of changes in gene expres-
sion signatures that occurred during allergic reactions to peanut
by profiling the transcriptomes of peanut allergic subjects at
multiple time points throughout the course of randomized,
double-blind, placebo-controlled challenges. Although such
challenges are considered the gold standard for characterizing
food allergy, they are not routinely performed because they are
resource-intensive. Rather than analyzing differences between
allergic and non-allergic individuals (i.e., case-control design used
in most studies of food allergy to date), our design allowed us to
leverage data collected at multiple time points and between
in vivo exposures (peanut and placebo) within the same indivi-
dual, increasing precision and power by minimizing bias due to
inter-individual variability, and optimizing relevance of findings
to actual human systems. Further, we were able to replicate our
major findings in a second cohort of 21 peanut allergic children.
We identified peanut genes (Table 2, Supplementary Table 2)
that exhibited significant changes in expression in response to
challenge with peanut but not placebo. Asserting the robustness
of our results, an overwhelming majority (93%) of the top peanut
genes identified in our discovery cohort were replicated in a
second independent cohort. We interpret the observed expression
signatures dominated by upregulation to be consistent with
activation of the acute-phase response to peanut allergen. Indeed,
the most significant peanut genes, including key drivers, are
ALOX5
BMX
SLC9A8
PHC2
HDGFRP3
MAR1
CEBPD
PFKFB4
FLOT2 GNB2
HAL
EXOC6
ACSL1
TMCC3
MAPK14
KLHL2
LTB4R
PADI4
IL1R2
ATP11A
ECHDC3
PPP1R3D
PTENP1
LOC100507006
RAB36
MAP2K6
CAMKK2
Peanut
Gene
Peanut 
Respon seGene
Key 
Driver
IL18R1
OR 1.3
P = 0.4
OR 2.9
P = 0.17
O
ve
ra
ll c
au
sa
lity
 fl
ow
OR 21.4
P = 2.0×10–6
OR 72.4
P = 1.9 × 10–11
OR 274.1
P =6.0×10–16
OR 0.0
P = 1.0
Fig. 5 Probabilistic causal gene network projection and key driver analysis identifies causal regulators of the peanut response module. Eiffel tower plot
depicting the probabilistic causal gene network for peanut response genes and its key drivers. The overall direction of causality flow is indicated by the
arrow to the right of the tower; genes at the highest levels have the greatest causal impact on the expression of genes in this network. Significant key
drivers (FDR≤ 0.05) in the network are depicted as filled diamonds, with gene name labels. All other genes in the network are shown as filled circles. As
per the legend, genes and key drivers are colored according to their designation as peanut response module gene (dark blue), both a peanut response
module and peanut gene (turquoise), or neither (gray). Odds ratios and P-values for the enrichment of genes at each path level (corresponding to path
length) for key drivers are shown to the left
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02188-7
8 NATURE COMMUNICATIONS | 8:  1943 |DOI: 10.1038/s41467-017-02188-7 |www.nature.com/naturecommunications
expressed by inflammatory cells with roles in immune activation,
immune effector functions, chemokine and cytokine signaling,
and cell migration and proliferation26–29, 34–37. These expression
trends and functional categories are similar to those recently
shown in a gene expression study of six subjects admitted to the
emergency room with anaphylaxis (including two individuals for
whom peanut exposure was the cause)38. Investigation in cohorts
with other food allergies will be required to determine the extent
to which expression of peanut genes are specific to the allergic
response to peanut.
As genes do not function in isolation, we constructed weighted
coexpression and probabilistic causal gene networks to model
molecular interactions and causal gene relationships, and applied
mathematical approaches (KDA) to identify and prioritize key
drivers of acute peanut allergic reactions. Indeed, effects of peanut
exposure on gene expression extended beyond single genes,
influencing networks of co-regulated loci involved in acute-phase
response and inflammatory processes. Specifically, peanut genes
were significantly over-represented in a single coexpression
module identified using WGCNA (Fig. 4). This peanut response
module of 2381 genes was highly enriched for pro-inflammatory
processes, including regulation of the Rel/nuclear factor-κB
(NF-κB) transcription factor family. NF-κB signaling has been
investigated extensively in asthma and allergy, and shown to
regulate key cytokines, chemokines, and cell adhesion molecules
in immune cells infiltrating sites of inflammation39, 40. A recent
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study employing WGCNA on transcriptomes of dust mite-
stimulated CD4+ T cells from asthmatic subjects found NFKBIA
(a member of the NF-κB family) to be one of nine hub genes
within the primary coexpression module identified41. This gene
and several others related to NF-κB regulation have also been
associated with genetic risk of asthma and related phenotypes42.
In contrast to other allergic diseases, NF-κB signaling in food
allergy has been less studied; however, its activation was recently
observed in a mouse model of intestinal anaphylaxis following
ovalbumin challenge43. Expression profiling in neonatal CD4+
T cells of food allergic individuals also revealed the dysregulation
of several genes involved in NF-κB signaling4.
Our probabilistic causal network and KDA identified and
prioritized six key drivers that most strongly and causally
modulated the peanut response module in the network (Fig. 5).
While little is known about KLHL2, ECHDC3, and PPP1R3D in
the immune response, LTB4R, PADI4, and IL1R2 have established
roles in inflammation. LTB4R encodes a receptor for leukotriene
B4 (LTB4) (Fig. 6), a lipid pro-inflammatory mediator involved in
the recruitment of leukocytes to sites of inflammation, including
neutrophils and macrophages26, 37, 44. Linked to biological pro-
cesses implicated by GO analyses, LTB4R and its ligand influence
the activation of NF-κB signaling44, 45. In addition, LTB4 and
LTB4R have previously been implicated in the pathogenesis of
atopic diseases, including asthma, atopic dermatitis, and allergic
rhinitis26, 46. PADI4, although not explicitly implicated in pro-
cesses associated with the allergic response, is a primary genetic
risk factor for rheumatoid arthritis (RA)27, a disease characterized
by systemic inflammation. The expression of PADI4 by various
inflammatory cells, namely neutrophils27, 47, 48, is elevated in
inflamed synovial RA tissue, and associated with increased levels
of RA-associated autoantibodies in humans and animal mod-
els49–51. IL1R2 is expressed by various immune cells, and gen-
erally considered to be a negative regulator of pro-inflammatory
IL-1 cytokine signaling, with roles in the production of inter-
leukins, as well the activation of NF-κB signaling52. Upregulation
of IL1R2 has been observed in peripheral blood mononuclear cells
of adult food allergic individuals5. In addition, variants in IL1R2
have previously been implicated in atopic disease28, 42, as well as
other inflammatory disorders52. Our probabilistic causal gene
network analysis additionally provided support for a directed
relationship between ECHDC3 and IL1R2 (Fig. 6).
Our study was intentionally designed to not focus on any one
peripheral blood cell-type, as multiple cell types have been
implicated in acute food allergic reactions, and discovery thus far
has been biased toward cell types sufficiently abundant for iso-
lation. Our leukocyte deconvolution approach was unbiased so as
to inclusively capture cellular expression signatures across per-
ipheral blood. Given limitations on the volume of blood that can
be collected from children, especially when sampling serially, flow
cytometry-based assays to target multiple cell populations at each
time point was not feasible. Our study provides data on 19
inferred leukocyte cell fractions (Fig. 3), highlighting three cell
subsets that could be directly profiled in future studies. Impor-
tantly, each of the significant cell subset changes were replicated
in our second peanut allergic cohort, bolstering the likelihood
that these changes represent genuine signatures associated with
acute allergic response to peanut. Among these, we observed that
naive CD4+ T cells decreased during peanut challenge. This is
perhaps not surprising, given that food allergy is classically
considered to be an IgE-mediated response orchestrated by Th2
T cells, which involves the activation of naive CD4+ T cells and
their transition to effector T cell types3. Decreases in naive CD4+
T cells could also reflect their migration from the periphery to
sites of inflammation. In contrast to the decrease of naive T cells,
the proportions of neutrophils and M0 macrophages both
increased in response to peanut, with neutrophils representing
~40% of cells on average in subjects four hours following expo-
sure. Both neutrophils and macrophages hold primary roles in
inflammation and allergic disease53, 54. For example, depletion of
macrophages and neutrophils in several mouse models influences
symptoms of peanut-induced anaphylaxis55–57. In humans,
markers of neutrophil activation, such as plasma myeloperoxidase
concentration, are significantly elevated in individuals experien-
cing acute anaphylaxis58. Interestingly, connecting cell-type
analyses to results from KDA, it is notable that the expression
of LTB4R, PADI4, and IL1R2 are linked to the function of mac-
rophages and neutrophils in the context of the inflammatory
response26, 49, 59–61. For example, inhibition of LTBR4 reduces
macrophage chemotaxis and inflammation59. Likewise, the infil-
tration of neutrophils and recruitment of effector T cells to
allergen-challenged sites is dependent on the expression of LTB4/
LTB4R by neutrophils26. In contrast, the expression of IL1R2 by
neutrophils has been shown to mediate pro-inflammatory effects
of IL-160. These results support the targeting of these cell types
for profiling of cell type-specific gene expression signatures in
acute peanut allergy.
Because the key drivers, molecular processes, and cell types
highlighted here were characterized in the context of changes
occurring directly during allergic reactions, they have potential to
inform the design and application of therapeutic strategies for
mitigating symptoms of peanut allergic reactions. Notably, a
subset of genes and biological processes highlighted by our
integrative analyses already serve as therapeutic targets for other
atopic and inflammatory diseases. For example, the key driver,
LTB4R, is modulated by 5-lipoxygenase inhibitors, which are in
clinical use for asthma; several LTB4R antagonists have also been
developed62. A biological process identified by our integrated
analysis, NF-κB signaling, is mediated by glucocorticoids63, which
are frequently administered for food allergic reactions. Also,
allergen-specific subcutaneous immunotherapy for environ-
mental allergies has been shown to suppress NF-κB signaling in
neutrophils of allergic individuals64. Several other inhibitors and
modulators of NF-κB signaling are in various stages of investi-
gation and development63, 65. It would be interesting to investi-
gate whether current treatment strategies can modulate peanut
genes and biological networks identified here, and generalize to
other food allergies as well.
In summary, we comprehensively profiled peripheral blood
transcriptomic changes in peanut allergic individuals during acute
allergic reactions. By adopting an integrative, data-driven
approach, we have identified key driver genes, biological pro-
cesses, and cell types associated with acute peanut allergic reac-
tions. Furthermore, we were able to replicate our major findings
in a second cohort. Our identification of six key driver genes
includes three previously associated with other allergic and atopic
diseases, as well as genes that remain less explored to date. This
combination of findings serves as a useful sanity check of our
results and indicates promise in targeting these genes and bio-
logical processes to further our mechanistic understanding of
peanut allergy, with the potential to inform development of new
treatment strategies.
Methods
Recruitment and sample collection. Subjects age 4–25 years with physician-
diagnosed peanut allergy or convincing history of peanut allergy with skin prick
test positive to peanut (wheal diameter ≥3 mm greater than saline control) or
detectable peanut specific IgE (ImmunoCAP >0.35 kUA/L) were eligible to parti-
cipate. Nineteen subjects were recruited from those undergoing screening oral food
challenges to determine eligibility for the CoFAR6 study9, a trial of epicutaneous
immunotherapy for peanut allergy at five study centers across the United States
including the Icahn School of Medicine at Mount Sinai, New York; University of
North Carolina Medical Center, Chapel Hill, North Carolina; Johns Hopkins
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University School of Medicine, Baltimore, Maryland; National Jewish Health,
Denver, Colorado; and Arkansas Children’s Hospital, Little Rock, Arkansas. These
nineteen subjects were the first CoFAR6 subjects undergoing screening oral food
challenges who consented to having additional blood drawn for transcriptomic
study. An additional two subjects were recruited from patients undergoing oral
food challenges as part of their clinical care of peanut allergy at the Icahn School of
Medicine at Mount Sinai, New York, NY during the same time period. The
institutional review boards of the participating institutions approved this study.
Written informed consent was obtained from all participants.
All subjects underwent randomized, double-blind, placebo-controlled oral food
challenges performed according to a modified AAAAI/EAACI PRACTALL
protocol8, 9. Following randomization by coin flip and under close medical
supervision with blinding of subjects and staff, each subject ingested incremental
amounts of peanut at 20 min intervals until allergic reaction or until final
cumulative dose of 1.044 grams protein ingested on one day, and ingestion of
equivalent incremental doses of placebo oat powder in similar fashion on another
day shortly before or after. The standardized doses ranged from 1mg to 600 mg
protein. The order of peanut and placebo challenges was randomized between
subjects, with subjects completing both peanut and placebo challenges. Intravenous
catheters allowed for 2.5 ml peripheral blood samples to be drawn right before
challenge (baseline), during the challenge (2 h from challenge start), and at the end
(4 h from challenge start) of the peanut and placebo challenges respectively into
Tempus tubes. Fixed collection time points were chosen to ensure uniformity in
collection strategy across peanut and placebo challenges performed by varying
blinded study personnel at different sites. The rationale for sampling at 2 h is that
experience at our study sites supports that most children who react during a peanut
challenge exhibit symptoms within the first 2 h. We additionally sampled at 4 h
because we hypothesized that adaptive immune responses could take longer to
manifest as gene expression changes, and 4 h is a typical length of time for a food
challenge visit to conclude.
Once a subject reacted with dose-limiting symptoms, the challenge was
terminated with detailed documentation of the cumulative dose at first objective
symptom, cumulative successfully consumed dose, and symptoms experienced by
the subject. Medications including antihistamines, epinephrine, IV fluids, IV
steroids, and beta-agonists were administered to the subject as needed according to
the study protocol, and the subject was closely monitored until all symptoms
resolved.
For the replication cohort, 30 additional children who also underwent double-
blind, placebo-controlled peanut challenges as part of the CoFAR6 trial were
eligible. Written informed consent was also obtained from these subjects with IRB
approval from the same institutions as the discovery cohort. Serial whole blood
collections were obtained following the same protocols used for the discovery
cohort. Subjects who did not react to peanut (n = 5) or did not have samples
collected during peanut challenge (n = 4) were then excluded, yielding a replication
cohort of 21 peanut allergic subjects.
Sample library preparation, sequencing, and data processing. RNA was iso-
lated from peripheral blood samples using Tempus Spin RNA Isolation kits
(Applied Biosystems). For the discovery cohort, all available samples from peanut
allergic children underwent RNA-seq library preparation and sequencing. For the
replication cohort, only samples from the peanut challenge of peanut allergic
children were processed and sequenced based on results from the discovery cohort
demonstrating that the placebo-related samples exhibited unremarkable gene
expression profiles (Supplementary Figure 2). Sequencing libraries for samples
from the discovery and replication cohorts were processed and sequenced
separately.
Following depletion of mitochondrial and cytoplasmic rRNA using Ribo-Zero
Gold rRNA Removal (Illumina), mRNA libraries were sequenced on the Illumina
HiSeq 2500 System with a per-sample target of 40–50 million 100 bp paired-end
reads, according to the manufacturer’s protocol. Read data were subjected to
quality control with FastQC and RNA-SeQC. The data in fastq format were
mapped to GRCh37 using the STAR v2.4.0g1 aligner (https://github.com/
alexdobin/STAR), and gene-level counts were estimated using HTSeq (https://pypi.
python.org/pypi/HTSeq).
Prior to statistical analyses, raw gene read counts were converted to cpm using
the edgeR66 package within R (www.R-project.org). Genes with systematically low
expression levels were removed, keeping only genes with c.p.m.> 0.1 in at least
10% of the samples analyzed (n = 17,337). Library sizes and normalization factors
were estimated, and counts were then normalized using edgeR and voom in the
limma R package67, 68, resulting in log2-cpms and weights for each gene.
Multidimensional scaling analysis was used to identify outlier RNA-seq samples,
resulting in removal of one sample (Supplementary Fig. 1) from the discovery
cohort. In addition, we used variancePartition69, to assess the contribution of
technical and biological factors to variation in gene expression across the samples.
This revealed minimal influence of age and gender (Supplementary Fig. 6), and
thus we did include these variables as covariates in the lme models next described.
Identifying genes associated with acute peanut reactions. For the 19 subjects in
the discovery cohort who reacted to peanut during their double-blind, placebo-
controlled food challenges, null and test lme models were constructed for each
gene, using the lme4 R package10. Each model included factor variables, “Time”
(baseline, two hours, and four hours), “Challenge” (peanut or placebo), “Order”
(which challenge came first), and “Weights” (voom output) as fixed effects, and per
subject variation and collection date as random effects. Differentiating the two
models was an interaction between the Time and Challenge variables (Time×-
Challenge) that was only present in the test model.
Null model: gene expression ~ Time + challenge + order + weights + individual
+ collection date + ε
Test model: gene expression ~ Time × challenge + order + weights + individual
+ collection date + ε
To identify genes with expression changes that occurred specifically during
peanut but not placebo challenge, we used a likelihood ratio test (LRT) to test for a
significant additional contribution of the interaction between time and peanut vs.
placebo exposure on gene expression in the test model when compared to the null
model. The LRT was implemented in R using the lmtest package (www.R-project.
org).
A similar approach was applied to RNA-seq data generated from the replication
cohort. However, because this cohort only included data from peanut challenges,
the LRT was used to test for an effect of “Time”.
Leukocyte deconvolution analyses. Raw RNA-seq read counts for genes used in
lme model analysis (n = 17,337) from 107 samples were first normalized using
DESeq270. We used CIBERSORT11 to estimate the proportions of leukocyte sub-
populations in each RNA-seq sample from DESeq2-normalized gene counts, using
the “L22” validated gene signature matrix;11 estimates and associated P-values were
based on 1000 permutations of the data, as implemented in the CIBERSORT
pipeline. To be inclusive of all individual samples in our data set, no significance
filter was applied to the estimated cell fractions. Following the same framework
used for gene expression analysis, for each of the cell types estimated, an LRT was
used to assess differences between null and test lme models, in which the test model
again included an interaction effect.
Null model: cell fraction ~ Time + challenge + order + individual + collection
date + ε
Test model: cell fraction ~ Time × challenge + order + individual + collection
date + ε
P-values produced by the LRT were FDR corrected using the Benjamini-
Hochberg method.
In the replication cohort, following the same methods for the inference of
leukocyte fractions from RNA-seq data using CIBERSORT, the LRT was used to
test for effects of “Time” on cell fraction, using equivalent models to those outlined
above for the gene expression analysis.
Coexpression network and gene ontology analyses. WGCNA was conducted
using the WGCNA and coexpp R packages (https://bitbucket.org/multiscale/
coexpp). To construct a weighted gene coexpression network for food allergy, 139
RNA-seq samples from food allergic children were used, including the 107 samples
from peanut allergic discovery cohort plus 32 samples from seven individuals with
non-peanut food allergies who were recruited from the Mount Sinai Allergy/
Immunology practice during the same study period and analogously sampled
during oral food challenges to their suspected food allergen (Supplementary
Table 5). The rationale for including samples from food allergic children more
broadly and not just those from peanut allergic subjects was that our goal was to
build a coexpression network for food allergy upon which we could then project
our peanut genes. Prior to WGCNA, the same expression level thresholds used
previously for the lme model analysis were applied to the data set, resulting in
17,328 genes. Gene counts were again normalized using edgeR/voom, and the
effects of collection date were removed. The resulting residuals were used for
weighted gene coexpression network construction. An adjacency matrix was gen-
erated by applying a power function (beta = 6; Supplementary Fig. 7) to a pair-wise
gene correlation (Pearson’s) matrix, initially estimated using per gene residual
values. This was then transformed into a topological overlap matrix, from which
module assignments were made using a dynamic tree cutting method.
We tested for enrichment of peanut genes in each module using the Fisher’s
exact test. Enrichments of coexpression modules for GO “Biological Process” terms
were assessed using GOrilla;16 the full set of genes input into WGCNA was used as
background.
Probabilistic causal gene network construction. We constructed a directed
probabilistic causal gene network by integrating peripheral blood gene expression
data from 526 patients with IBD20 and eQTL using RIMBAnet19, 24, 25, a software
package we developed for constructing integrative molecular Bayesian networks. As
these networks do not scale linearly with increasing nodes, we took the top 25% of
varying genes to build this network19, 25. Continuous data was used for calculating
partial priors, which are then used as priors in the network construction. Addi-
tional priors included genes that are cis eQTLs. For the eQTL priors, if a gene also
has a strong eQTL associated with it in cis, such a gene can be considered as a
parent node, given the genotype cannot be the effect of a gene expression change.
The data was discretized into three states for each gene: high expression levels, low
expression levels, and unexpressed. This is done by first normalizing the values for
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each gene to ensure a normal distribution. Then, k-means clustering (k = 3) is used
with the option of dropping groups should there not be enough members to fill it
to assign the values for each sample. In a case for which there are only two clusters
they would be classified as high and low19, 24, 25.
To support our use of the IBD network, a peanut allergy-specific replication
causal network was constructed using data from the peanut allergic discovery and
replication cohorts. Specifically, the same genes that were used as input for the IBD
network that were also expressed in the peanut allergic cohorts (n = 7055) were
used. The data were discretized in the same fashion as the IBD data with analogous
use of RIMBAnet19, 24, 25 to construct a probabilistic causal network.
Key driver analysis. Key driver analysis was conducted using the KDA package in
R17. The package first defines a background subnetwork by looking for a neigh-
borhood K-steps away from each node in the target gene list in the network. Then,
stemming from each node in this subnetwork, it assesses the enrichment in its k-
step (k varies from 1 to K) downstream neighborhood for the target gene list. In
this analysis, we used K = 7. KDA was run on both the IBD network as well as the
peanut allergy-specific causal network.
Data availability. Data for this study (doi:10.7303/syn10212437) is available via
Synapse, a software platform for open, reproducible data-driven science. The direct
link to the data is: https://www.synapse.org/#!Synapse:syn10212437/files/.
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